Table 3

Impact of disease activity statuses on mortality, new damage and severe new damage: univariable and multivariable analyses

Remission (on/off therapy)LDAS
HR (95% CI)p ValueHR (95% CI)p Value
Mortality
 Unadjusted0.46 (0.17 to 1.27)0.13300.65 (0.26 to 1.60)0.3454
 Adjusted*0.56 (0.20 to 1.55)0.26230.81 (0.32 to 2.02)0.6476
New damage†
 Unadjusted0.53 (0.38 to 0.75)0.00030.61 (0.44 to 0.85)0.0032
 Adjusted*0.60 (0.43 to 0.85)0.00420.66 (0.48 to 0.93)0.0158
Severe new damage‡
 Unadjusted0.31 (0.15 to 0.64)0.00140.48 (0.26 to 0.92)0.0260
 Adjusted*0.32 (0.15 to 0.68)0.00330.54 (0.28 to 1.03)0.0614
New damage (non-GC)§
 Unadjusted0.45 (0.31 to 0.66)<0.00010.56 (0.40 to 0.80)0.0013
 Adjusted*0.51 (0.35 to 0.75)0.00060.62 (0.43 to 0.87)0.0067
Severe new damage (non-GC)¶
 Unadjusted0.25 (0.10 to 0.62)0.00280.30 (0.12 to 0.74)0.0091
 Adjusted*0.31 (0.12 to 0.75)0.01010.35 (0.14 to 0.85)0.0206
New damage (GC)**
 Unadjusted1.06 (0.59 to 1.92)0.84761.24 (0.69 to 2.23)0.4682
 Adjusted*0.99 (0.53 to 1.84)0.96971.34 (0.74 to 2.42)0.3333
  • *Adjusted by age at baseline, gender, ethnicity, socioeconomic status, years of instruction, medical coverage and first SLICC/ACR damage index (SDI).

  • †One-point increment in the SDI.

  • ‡Three-point increment in the SDI.

  • §One-point increment in the damage unrelated to glucocorticoids.

  • ¶Three-point increment in the damage unrelated to glucocorticoids.

  • **One-point increment in the damage glucocorticoids-related damage.

  • LDAS, low disease activity status; reference group for HRs: non-optimally controlled.